Ruga Corp., of Houston, said the company's name has changed to Aravive Biologics Inc. and it moved its business operations to Houston following the award of a $20 million grant from the Cancer Prevention and Research Institute of Texas, which is supporting the development of drug candidate Aravive-S6 as a potential treatment for acute myelogenous leukemia and solid tumors, including ovarian, pancreatic and breast cancers.